Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Health Innovation Manchester and The University of Manchester has today (14 October 2024) announced a groundbreaking ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...